Pfizer’s already beaten Ed Miliband. Now it just needs to offer the right price
Pfizer will almost certainly have to offer more than its second bid of £50 a share for rival drug giant AstraZeneca, but the American predator seems to be winning the game of spin so far. For a start, Pfizer chief Ian Read turns out to be a Scottish-born graduate of Imperial College London who has spent his entire career with the company. AstraZeneca, by contrast, is run by a Frenchman, Pascal Soriot, under a Swedish chairman, Leif Johansson, both parachuted in two years ago — reminders that AstraZeneca is already a multinational with its research facilities divided between Cheshire and Sweden and less than 15 per cent of its workforce
